Navigation Links
NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
Date:11/8/2012

IPSWICH, Mass., Nov. 8, 2012 /PRNewswire/ -- New England Biolabs (NEB) has recently received a $640,000 Phase II Small Business Innovation Research (SBIR) grant to expand its research and product development of novel enzymatic tools for epigenetic analysis. This latest grant adds to the more than $1.1 million of SBIR funds awarded for this research since 2009.

(Logo:  http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b )

Since its establishment in 1974, NEB has been dedicated to the discovery and development of reagents for the life sciences industry. A key to this effort has been the focused development of recombinant enzyme technology by NEB scientists, resulting in  a wide array of enhanced tools for molecular biology research and analysis, such as engineered restriction enzymes with greater specificity under a wider range of reaction conditions. This commitment has placed NEB at the forefront of restriction enzyme research and supply.

The use of restriction enzymes in epigenetic studies has been a research focus at NEB for many years. Specifically, research in the area of methylation-dependent and methylation-sensitive restriction enzymes has led to the discovery and commercialization of new tools to identify these DNA modifications. For example, in 2010, NEB scientists identified the MspJI family of restriction enzymes, which has the ability to excise small fragments of methylated DNA for use in epigenetics studies. This latest SBIR grant award enables further research in this area, and ultimately a deeper understanding of epigenetic marks in the mammalian genome.

"Since its founding, NEB has coupled its basic research with the development of new tools for molecular biology," states Dr. Bill Jack, Director of Research at NEB. "The repository of knowledge, generated during the almost four decades of restriction endonuclease study at NEB, has fueled a discovery program that has radically expanded the utility of restriction endonucleases and activity on a variety of DNA templates, including those created by epigenetic modification. We are committed to continuing this discovery process, and to use these novel new enzymes to uncover the role of epigenetic modification during development, differentiation and disease." 

For more information on the use of restriction enzymes in epigenetics research, visit www.epimark.com.


'/>"/>
SOURCE New England Biolabs
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. HealthTech Capital Announces Awards for the HealthTech Conference 2012 - Building a Business in the New HealthTech Ecosystem
2. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
3. NSF awards $1.2 million grant to Clemson professor for energy storage research
4. OBNs 2012 Annual Awards Dinner Celebrates UK Bioscience Success Stories
5. JPM-TMT Awards New Contract to Study Administration using Marburg Virus Drug
6. NSF awards $450,000 to UNH, Conductive Compounds Inc. for solar panel innovation
7. Grifols Awards Winners of the 9th Annual eALTA Research Fellowship at 2012 ERS Meeting
8. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
9. The Masonry Heater Association of North America Announces the 2012 Masonry Heater, Bake Oven and Masonry Project Awards
10. picoSpin-45 Benchtop NMR Spectrometer a Finalist in the European Life Sciences Awards
11. San Diego Medical Director Wins Two Book Awards For Latest Medical Thriller
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... BARBARA, CALIFORNIA (PRWEB) , ... April 20, 2017 , ... ... optimization firm for the life sciences and healthcare industries, is pleased to announce ... the new established USDM subsidiary “USDM Europe GmbH” based in Germany. , Braemer ...
(Date:4/20/2017)... - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or ... Congress ("ILC") 2017 of the European Association for the Study ... on the positive effects of PBI-4050 on reduction of non-alcoholic ... syndrome. ... Lyne Gagnon, Vice-President of R&D Pre-clinical of Prometic "This extensive ...
(Date:4/20/2017)... MD (PRWEB) , ... April 20, 2017 , ... ... the formation of a unique intellectual property (IP) sharing and commercialization model. , ... most promising inventions. A main component of this effort is bringing the IP ...
(Date:4/20/2017)... 2017 For today, Stock-Callers.com redirects investors, ... development and clinical research aimed at treating diseases and medical ... Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), ... can access our complimentary research reports on these stocks now ... http://stock-callers.com/registration ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):